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a b s t r a c t
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased
maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of
PNH during pregnancy. We describe a case of a 30 year old female with hypoplastic myelodysplastic
syndrome and PNH. After two years of treatment with eculizumab, she became pregnant. She developed
breakthrough hemolysis at 20 weeks gestation. Pharmacokinetic and pharmacodynamic studies
demonstrated a subtherapeutic eculizumab level with absence of complement blockade. Escalation of
her eculizumab dose successfully controlled hemolysis and restored therapeutic eculizumab level and
activity. She delivered a healthy baby at 36 weeks.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired
clonal stem cell disorder characterized by intravascular hemolysis
and thrombophilia. Pregnancy in PNH is associated with increased
maternal and fetal morbidity and mortality due to thromboembo-
lism, infection and premature birth [1]. Therefore, PNH has been
considered a relative contraindication for pregnancy. The terminal
complement cascade inhibitor eculizumab has become the stan-
dard treatment in patients with symptomatic PNH. There are
limited published data regarding the use of eculizumab in preg-
nancy in either animal studies or in humans. We report a patient
with PNH who became pregnant while on eculizumab, required
dose escalation during the third trimester to control breakthrough
hemolysis, and successfully delivered a healthy baby.
2. Materials and methods
Eculizumab levels were measured at Cambridge Biomedical
using a manual ELISA method in which the microtitre plates are
coated with C5, then blocked. Standards, controls, and unknowns
were added. After incubation and washing, mouse anti-human
IgG4 horseradish peroxidase (HRP) was added as the conjugate.
Then the substrate 3,30,5,50-tetramethylbenzidine (TMB) was
added and the color reaction was halted using a stop reagent.
The results were read spectrophotometrically at 450 nm using a
plate reader [2]. The pharmacodynamics of eculizumab were
determined by measuring the capacity of the patient's serum to
lyse chicken erythrocytes in a standard total human serum-
complement hemolytic assay [3].
2.1. Case report
A 30 year old Chinese female presented with pancytopenia and
direct antiglobulin negative hemolytic anemia in 2010. She was
diagnosed with hypoplastic myelodysplastic syndrome due to
dysplastic feantures noted on the bone marrow aspirate and
biopsy, although with normal cytogenetics. A PNH clone was
identiﬁed by ﬂow cytometry with type I RBC 93.9% (reference
range – 99.0 to 100.0%), type II RBC 0.10% (reference range – 0.00
to 0.99%) and type III RBC 6.00% (reference range – 0.00–0.01%).
Her granulocyte clone size was 52.93% (reference range – 0.00–
0.01%). She was treated with cyclosporine, horse anti-thymocyte
globulin, steroids and standard dose eculizumab with a good
response. Her lactate dehydrogenase (LDH) levels returned to
normal with a simultaneous improvement in her hemoglobin
level from 6 g /dl to 12 g/dl. She no longer required blood nor
platelet transfusion. She had no thrombotic events. She was
advised against pregnancy and urged to use non-hormonal contra-
ceptives. Two years after the initial diagnosis, she was noted to
have a decline in hemoglobin from 12 g/dl to 7 g/dl with a
simultaneous rise in LDH to 1027 U/L and undetectable haptoglo-
bin (Fig. 1). A repeat bone marrow aspiration and biopsy showed
focal erythroid hyperplasia, mild dyserythropoiesis, normal mye-
lopoiesis, small lymphoid aggregate, and increased iron stores.
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There was no evidence of clonal evolution based on cytogenetics.
The PNH granulocyte clone size increased to 90%. On further
investigation, she was found to be pregnant at 20 weeks gestation.
Full anticoagulation with enoxaparin was begun due to the
increased risk of thrombosis. She continued therapy with eculizu-
mab 900 mg every 2 weeks. She required an average of 1 unit of
packed red blood cell transfusion per week for symptomatic
anemia (Fig. 1). At week 30, her serum eculizumab level was
found to be less than 11 ug/ml (therapeutic499 ug/ml). Pharma-
codynamic (PD) assay showed no complement blockade by eculi-
zumab. She was re-induced with eculizumab 900 mg IV weekly x
4 doses, followed by 1200 mg IV every 2 weeks. Repeat eculizu-
mab level after 5 weeks was 100 ug/ml with complete comple-
ment blockade by PD assay and her hemolysis was controlled
(Fig. 2). Her hemoglobin rose to 10.8 g/dl without further blood
transfusion. She did not have evidence of pre-eclampsia nor
proteinuria. She had an elective Cesarean section at 36 weeks
and gave birth to a healthy female baby with APGAR score 9/9.
Eculizumab levels were undetectable in both cord blood and
breast milk. She continued anticoagulation in the postpartum
period. No thrombotic nor bleeding complications were noted in
the postpartum period. She continued on eculuzimab 1200 mg
every 2 weeks for 3 months postpartum with stable hemoglobin
and no evidence of active hemolysis. She remains stable on
eculizumab, the dose of eculizumab was reduced to 900 mg every
2 weeks
3. Discussion
sThe median age at diagnosis of PNH is 34 years, so affected females
are often in the reproductive age group. PNH is not known to adversely
affect female fertility. There are 6 reported cases of successful pregnan-
cies in PNH patients being treated with eculizumab [4–7]. Kelly et al.
described the ﬁrst 3 women who received eculizumab during preg-
nancy [4]. Two of these patients suffered from breakthrough hemolysis
in the third trimester. Breakthrough hemolysis manifested itself with
patients experiencing hemoglobinuria prior to their next scheduled
dose of eculizumab. Both of these patients were treated by reducing the
interval between subsequent doses from 14 days to 12 days in one case
and to 7 days in the other case. The third patient delivered at 28 weeks
due to preeclampsia. Three other cases have been described [5–7]. One
of them suffered breakthrough hemolysis and was treated by reducing
the duration between eculizumab doses to 7 days [7].
We describe the seventh case of successful pregnancy in the era
of eculizumab. Our patient was stable on standard dose eculizumab
until the second trimester. It has been noted that the dose of
eculizumab required to block complement during the latter stages
of pregnancy is greater than in the non-pregnant state [4]. Our
patient developed breakthrough hemolysis in the second trimester
despite standard eculizumab administration. Her eculizumab level
was sub-therapeutic and a pharmacodynamic assay demonstrated
the absence of complement blockade. Rather than reducing the time
interval between doses, we opted to escalate the dose of eculizumab.
Higher doses of eculizumab have been needed to control atypical
hemolytic uremic syndrome (aHUS) [8] and catastrophic antipho-
spholipid syndrome [9]. In aHUS, the recommended dose of eculi-
zumab is 33% higher than for PNH in order to completely block the
complement cascade [10]. Utilizing this escalated dose of eculizumab,
we successfully achieved therapeutic eculizumab levels with ade-
quate complement blockade (Fig. 2) and controlled the patient's
hemolysis (Fig. 1). This dose of eculizumabwas also recently reported
in a pregnant patient with aHUS and found to be safe [11].
Pregnancy activates the complement cascade, with increased
terminal complex formation in the third trimester [12]. We
hypothesize that loss of control of complement-mediated hemo-
lysis with eculizumab during the second and third trimester
appears to be due to the physiologic expansion of intravascular
volume which occurs during pregnancy. Our patient's serum
eculizumab level was clearly subtherapeutic, reﬂecting the dilu-
tion which had occurred. Dose escalation restored the level to
therapeutic range and controlled hemolysis.
Eculizumab levels were not detectable in our patient's cord
blood nor breast milk. It therefore does not appear to cross the
placenta nor be excreted in breast milk, which is consistent with
previous reports [4–7]. Forty-ﬁve percent of pregnancies in
women with PNH result in spontaneous miscarriage and 6% in
maternal mortality due to fatal thrombotic events [13]. Because of
the risk of life threatening thrombotic complications, pregnant
women with PNH should receive full anticoagulation during
pregnancy and for at least 4–6 weeks postpartum [14].
Our case highlights that breakthrough hemolysis can occur
early in gestation and that pregnant patients with PNH require
close monitoring. It appears that eculizumab can be safely used
throughout pregnancy. Many PNH patients require either a short-
ening of dose interval or treatment with higher doses of eculizu-
mab in order to control hemolysis as pregnancy progresses.
Fig. 1. Trend of LDH and hemoglobin measured at Baseline, 4 weeks (calculated
retrospectively), 20 weeks, 27 weeks, 30 weeks and 35 weeks.
Red cell transfusion indicated by red arrows.
Small black arrows represent eculizumab 900 mg every 2 weeks.
Large black arrows represent eculizumab 900 mg weekly x 4 doses followed by
1200 mg every 2 weeks.
Fig. 2. Complement activity by pharmacodynamic assay (PD) shown on left Y axis.
Eculizumab level by pharmacokinetic assay (PK) shown on right Y axis. Graph
depicts fully active complement system with subtherapeutic eculizumab level
before re-induction (week 0) and complete blockade of complement activity with
therapeutic eculizumab levels.
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